Genentech, Inc.

Ac Immune Sa

Katholieke Universiteit Leuven

Isidro Hotzel

Oskar Adolfsson

Gai Ayalon

Danielle Marie Di Cara

Paul J Carter

Christoph Spiess

Diego Ellerman

Mark S Dennis

Robert F Kelley

Teemu T Junttila

Ji Li

Danielle Dicara

Yonglei Shang

Justin M Scheer

Xiaocheng Chen

Devin Tesar

Danielle DiCara

Jagath Reddy Junutula

Andrea M Pfeifer

Andreas Muhs

Jo-Anne Hongo

Maria Pihlgren

Meredith C Hazen

Shang-Fan Yu

Dhaya Seshasayee

Yi-Chun Hsiao

Zhonghua Lin

Fred Van Leuven

Sunil Bhakta

Justin Scheer

Benny Chih

Ainhoa Echeverria Larraza

David Verne Hansen

Lisa Bernstein

Frank-Peter Theil

This application discloses, inter alia, certain antibodies that specifically bind to human TREM2 (triggering receptor expressed on myeloid cells 2). In some embodiments, the antibodies act as TREM2 agonists. In some embodiments, antibodies herein specifically bind to the stalk region of intact, human TREM2, without binding to soluble TREM2, which is the product of TREM2 cleavage between residues H157 and S158. In some embodiments, the antibodies act as TREM2 agonists, specifically bind to the stalk region of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50 pM, or 1-10 pM, specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site, and do not bind to soluble TREM2. In some embodiments, antibodies herein also inhibit shedding of soluble TREM2 in a human microglia cell model and in vivo in a mouse model, decrease levels of soluble TREM2 in plasma, CSF and/or the brain, enhance survival of human microglia cells, and increase Aβ plaque formation and compaction in a human microglia model (for example, as measured by increased Aβ plaque intensity and/or increased X04 plaque intensity in human microglia), and thus, may provide a number of neuroprotective activities.

Agonists of TREM2

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

Humanized and affinity matured antibodies to FcRH5 and methods of use

The present invention relates to polypeptide expression systems and methods of using the same.

Polypeptide expression systems

The invention provides anti-Tau antibodies and methods of using the same.

Anti-Tau antibodies and methods of use

Anti-tau antibodies and methods of use

The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.

Expression and secretion system

Anti-Tau Antibodies and methods of use

Growing community of inventors

Brisbane, CA, United States of America

Isidro Hotzel